NeuroLens - Ultra-high Resolution Detection of Pathologic Protein Aggregation in the Human Brain
Forthcoming · Austria, Germany, Spain, Netherlands, Belgium
Source: EU Funding & Tenders Portal
Progressive supranuclear palsy (PSP) is a fatal, rare 4-repeat tauopathy for which no disease-modifying therapy exists and no validated early biomarker is available. Patients endure a diagnostic odyssey exceeding four years after symptom onset, driven by poor early-stage sensitivity of clinical criteria and the inability of conventional PET systems to resolve relevant small subcortical nuclei. As
- Status
- Prospective
- Sector
- Hospital
- Location
- Austria, Germany, Spain, Netherlands, Belgium
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about NeuroLens - Ultra-high Resolution Detection of Pathologic Protein Aggregation in the Human Brain
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Progressive supranuclear palsy (PSP) is a fatal, rare 4-repeat tauopathy for which no disease-modifying therapy exists and no validated early biomarker is available. Patients endure a diagnostic odyssey exceeding four years after symptom onset, driven by poor early-stage sensitivity of clinical criteria and the inability of conventional PET systems to resolve relevant small subcortical nuclei. As tau-targeting therapies are now entering clinical development, accurate early staging is essential to enable biomarker-guided therapeutic trials in PSP and in broader tauopathies including Alzheimer's disease. NeuroLens addresses this unmet need by generating robust, EU Medical Device Regulation (MDR)-compliant clinical evidence for a breakthrough orphan PET/MRI insert designed for 3-Tesla scanners. The device achieves sub-millimetre effective spatial resolution and more than twice the sensitivity of standard whole-body PET systems, enabled by high-resolution 3D Time-of-Flight detectors with AI-assisted Depth-Of-Interaction determination and a physics-informed AI reconstruction pipeline integrating simultaneous 4D MRI motion fields and multi-frame super-resolution. Using the orphan-designated tau tracer [18F]PI-2620, a prospective, blinded, multinational diagnostic accuracy study will enrol 180 early-stage PSP participants across Germany and Spain with 18-month longitudinal follow-up. Primary targets include a diagnostic sensitivity gain of at least 15% over standard PET and a reduction in median diagnostic delay of at least 30%. The project will finalise a CE-submission-ready MDR Annex XIV/XV dossier, release FAIR datasets and open-source software, and deliver harmonised adoption kits for EU-wide rollout. The interdisciplinary consortium of eight partners from five EU Member States integrates imaging engineering SMEs, expert clinical hubs, and an SSH partner to ensure a patient-centred, gender-sensitive approach throughout. |
Location
Country | Austria, Germany, Spain, Netherlands, Belgium |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2026-11-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
